Compounds > dapsone, methyluracil drug combination
Page last updated: 2024-12-10

dapsone, methyluracil drug combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3080915
MeSH IDM0121509

Synonyms (10)

Synonym
dapsone - methyluracil
methyluracil-dapsone (2:1)
69422-71-5
dimotsifon
dapsone, methyluracil drug combination
dimocifon
methyluracil-dapsone (2:1) compd
dimocifone
DTXSID70219581
4-(4-aminophenyl)sulfonylaniline;6-methyl-1h-pyrimidine-2,4-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (16.67%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		4.661pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
dapsone
[no description available]		4.661substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
diucifon
diucifon: contains 6-methyluracil & p,p-2,4-dihydroxy-6-methylpyrimidinyl-5-sulfonaminodiphenylsulfone		3.3511
ConditionIndicatedRelationship StrengthStudiesTrials
Chronic Illness
[description not available]		02.6630
Infections, Staphylococcal
[description not available]		02.3720
Group A Strep Infection
[description not available]		01.9610
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.6630
Pyoderma
Any purulent skin disease (Dorland, 27th ed).		02.3720
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.3720
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		01.9610
Hansen Disease
[description not available]		03.3511
Leprosy
A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.		03.3511
Pemphigus Foliaceus
[description not available]		01.9710
Pemphigus
Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.		01.9710
Eczema, Atopic
[description not available]		02.3720
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		02.3720